Liver-Specific ISX and p53 Knockout Mouse Model for Rapid Cancer Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatocellular carcinoma (HCC) are ineffective beyond early diagnosis and surgical intervention, and the pathogenic mechanisms of non-alcoholic fatty liver disease (NAFLD) and its progression to liver cancer remain poorly understood, lacking relevant biomarkers.
Innovation Solution
A liver-specific ISX gene expression and p53 gene knockout transgenic mouse model is developed, where mice are fed a high-calorie diet to induce fatty liver and subsequent liver cancer, mimicking human metabolic diseases and allowing for the study of disease mechanisms and potential treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional mouse models are used to study liver cancer, then the disease development process is slow and takes a long time, but this reduces the efficiency of research and treatment development
Solution Approach 1:
The patent applies preliminary action by pre-establishing mice with liver-specific ISX gene expression and p53 gene knockout before feeding them high-calorie diet. This genetic preparation accelerates the disease progression, allowing fatty liver, fibrosis, and cancer to develop much faster than in conventional models, thereby reducing research time while maintaining biological relevance
Solution Approach 2:
The patent changes key biological parameters by creating a transgenic model with specific gene expressions (ISX upregulated, p53 knocked out) that fundamentally alters the disease progression rate and pathway. This genetic parameter modification enables rapid development of liver cancer within months rather than years, significantly improving research productivity
2Loss of information
If comprehensive study of NAFLD pathogenic mechanisms is conducted, then understanding of disease etiology improves, but lack of relevant biomarkers and effective models hinders research progress
Solution Approach 1:
The patent segments the complex NAFLD-to-cancer progression into distinct stages (fatty liver, fibrosis, cancer) that can be studied sequentially in the same model system. The liver-specific gene modifications allow each stage to be investigated independently while maintaining the complete disease pathway context, making comprehensive mechanism study more feasible
Solution Approach 2:
The transgenic mouse model serves as an intermediary that bridges the gap between basic science and clinical application. By incorporating specific gene expressions and knockouts, the model provides accessible biomarkers and mechanistic insights that can be translated to human disease, overcoming the previous lack of relevant biomarkers and effective models
3Reliability
If early diagnosis and surgical operation are performed, then patient survival improves, but effective treatment options remain limited beyond these interventions
Solution Approach 1:
The patent creates a copying of the human disease process in mice through precise genetic modeling (ISX expression and p53 knockout that replicates human NAFLD progression). This allows researchers to test and develop new treatment options in a biologically relevant model before clinical application, expanding treatment versatility while maintaining the reliability of early intervention strategies
Data Source
AI summary
A liver lesion-mouse model which is a liver-specific ISX gene expression and p53 gene knockout transgenic mouse, wherein liver lesion develops after the mouse is fed with a high calorie diet.